MARKET NEWS

Phillips-Medisize Continues to Attract Industry Thought Leaders to Connected Health Team
Novan Announces Promising Clinical Results With SB414
Immunocore Announces Start of Phase I ImmTAC Study in Patients with Solid Tumors  
RedHill Biopharma Receives Allowance for New US Patent Covering Encapsulated Bowel Preparation
Q BioMed Announces FDA Filing for Strontium Chloride Sr89 Injection USP for Relief of Metastatic Cancer Bone Pain
Evotec & Novo Nordisk Form Strategic Research Alliance

  FEATURED EDITORIAL

  COMPANY PROFILE

FrontageAt Frontage, we closely collaborate with pharmaceutical and biotech companies to help them bring promising drug candidates to market. With 14 locations in the US and China, Frontage has been assisting clients in their drug development efforts since 2001. We are committed to providing rigorous scientific expertise to ensure the highest quality and compliance on each project. Spanning from preclinical through late-stage development, our full-service offerings include DMPK, bioanalysis using 60+ LC-MS/MS instruments, analytical testing, product development, and full biometrics support. Frontage also provides turnkey product development services to generic, innovator and consumer health companies to support IND, NDA, ANDA, and 505(b)(2) submissions. Click here for more.

  EXCLUSIVE ONLINE CONTENT

ImmunoBiochem

CCAB Partners With ImmunoBiochem as it Launches New Co-Development Strategy to Advance Early-Stage Biotech Companies

The Centre for the Commercialization of Antibodies and Biologics (CCAB) and ImmunoBiochem Corporation have announced an agreement that will see CCAB provide a new investment to help advance ImmunoBiochem’s novel breast cancer therapeutic candidate one step closer to the clinic.

Merch, Rexahn

Rexahn Pharmaceuticals Announces Clinical Collaboration With Merck

Rexahn Pharmaceuticals, Inc. recently announced it has entered into a clinical trial collaboration agreement with Merck (known as MSD outside the United States and Canada) to evaluate the combination of Rexahn’s RX-5902 and Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab) in a Phase 2 trial in patients with metastatic triple negative breast cancer (TNBC).

Pfizer, Astellas

Pfizer & Astellas Amend Clinical Research Protocols for Two Phase 3 Trials

Pfizer Inc. and Astellas Pharma Inc. recently announced amendments to the protocols for two registrational Phase 3 trials, ARCHES and EMBARK, designed to evaluate the safety and efficacy of XTANDI (enzalutamide) in men with hormone-sensitive prostate cancer (HSPC).

Sol-Gel Technologies Announces Collaborative Agreement With Perrigo

Sol-Gel Technologies Announces Collaborative Agreement With Perrigo

Sol-Gel Technologies Ltd. recently announced it has entered into a collaborative agreement with Perrigo Israel, an affiliate of Perrigo Company plc, for the development, manufacturing, and commercialization of a generic product candidate.

Clementia Announces Completion of Enrollment in Phase 3 MOVE Trial

Clementia Announces Completion of Enrollment in Phase 3 MOVE Trial

Clementia Pharmaceuticals Inc.recently announced the early completion of patient enrollment in the MOVE Trial, Clementia’s registrational Phase 3 clinical study evaluating the safety and efficacy of palovarotene for the treatment of patients with fibrodysplasia ossificans progressiva (FOP).

Drug Devices

Nevakar & Endo Enter Exclusive Licensing Agreement for Multiple 505(b)(2) Injectable Products

Nevakar Inc. recently announced it entered into an exclusive licensing agreement with Endo International plc’s subsidiary, Endo Ventures Limited, for the development of five differentiated, sterile injectable products in the US and Canada.